IGS PHARMA
Board
2 directors, since incorporationDirector (not named in the articles)
since 16-12-2019
term without a fixed end
listed in the 2025 annual accounts, filed on 09-06-2026
Director (not named in the articles)
since 16-12-2019
term without a fixed end
listed in the 2025 annual accounts, filed on 09-06-2026
Mandates through the years
2 names, the dashed line is todayDirector (not named in the articles)
Director (not named in the articles)
Board
Mandates as a list
-
- Director (not named in the articles), from 16-12-2019 to date
-
- Director (not named in the articles), from 16-12-2019 to date
Control
Founders
,
This company
IGS PHARMA
Equity -€155,693
Loss €97,048 in 2025
Capital
- Contribution
- €1,000
- Shares
- 100
- Contribution per share
- €10
- Equity per share
- -€1,557 in 2025
- Source
- deed of 20-12-2019
Articles of association
deed of 20-12-2019 (in French)- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
- Transfer restrictionThis rule says whether shareholders may sell their shares freely or need approval first.
- “Moitié à charge cédant et moitié à charge acquéreurs,proportionnellement nombre actions si plusieurs, tous cas cessions entre vifs,à titre…”
Shareholders
At incorporation
deed of 20-12-2019 ↗
- 50 shares (50%) · €500
- 50 shares (50%) · €500